The mechanism is the program: a lead reclassified, a clearance model fixed, a lithium biomarker

A lead gets reclassified

CVN636, a CNS candidate, is not what it was thought to be, and the corrected identity is better. In a preprint, Lin, Niswender, Asher, and Javitch showed the compound acts as a positive allosteric modulator that enhances orthosteric agonist responses rather than acting as a direct agonist. The difference matters: a PAM only turns the volume up when the natural signal is present, instead of forcing the receptor on. m:…6030

The selectivity is equally precise. CVN636's activity is restricted to mGlu7/7 homodimers and does not extend to mGlu7-containing heterodimers. And the mechanism check was clean: blockade of orthosteric agonist binding with a competitive antagonist abolished the compound's activity, which is exactly what a genuine agonist-dependent PAM should do. Mechanism precision like this is what lets a program dose and design trials with confidence. m:…6030

The reclassification is good news for the program. A direct agonist risks driving the receptor hard all the time, with desensitization and off-target effects as the price. A PAM that respects the receptor's own timing and picks out homodimers from heterodimers is a scalpel where the previous assumption was a hammer. The finding does not make CVN636 a drug, but it makes its pharmacology legible. m:…6030

The missing protein in clearance math

Clearance models had a missing protein and did not know it. In a preprint, Wen and colleagues showed that FABP1, the liver fatty acid binding protein, interacts with CYP2C9 and alters the kinetics of metabolite formation in human liver microsomes. It is the sort of protein-protein interaction that standard assays quietly absorb into the noise. m:…3768

The numbers argue for paying attention: CYP2C9 and FABP1 expression together provided the best predictive model for probe-substrate hydroxylation in human liver S9 fractions, and folding FABP1 expression and protein-protein interactions into PBPK models significantly improved in vivo hepatic clearance prediction. The cautious reading is that clearance predictions built on microsome assays without this interaction carry an error the PBPK improvement now quantifies. m:…3768

The fix is also a warning. If omitting FABP1 moves clearance predictions, every PBPK model for CYP2C9 substrates built without it carries a hidden bias, and those predictions feed first-in-human dosing. My read: the cheapest interpretation is that the field's clearance models are slightly wrong in a systematic direction; the expensive one is that some programs already paid for the error. m:…3768

Lithium's kidney ledger

Lithium's kidney side effects may have a single molecular thread to pull. In a preprint, Zerarga found that GDF15 induction in the kidney is a key driver of lithium-induced polyuria and microcystic remodeling, and in lithium-treated patients, urinary GDF15 levels were a strong determinant of maximal urine concentrating ability. The biomarker is not a bystander. It tracks the damage. m:…2164

The causal evidence came from mice: global GDF15 deletion attenuated lithium-induced polyuria and prevented microcyst formation. A biomarker that is also a driver is the rarest kind of finding. It gives clinics a urine test to watch and gives developers a target to hit. Lithium remains a cornerstone psychiatric therapy, and a way to separate its benefits from its kidney costs has been a long time coming. m:…2164

The trajectory from here is straightforward to sketch. Urinary GDF15 becomes a monitoring candidate for patients on long-term lithium, a urine test that asks less of the patient than a kidney biopsy. And if GDF15 drives the remodeling, blocking its signaling becomes a therapeutic hypothesis worth testing against the drug's psychiatric benefit. Two different product shapes from one protein. m:…2164